Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus kidney drug trial halted midway

NCT ID NCT05781750

Disease control Sponsor: Kezar Life Sciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Participants had to meet specific kidney and blood health criteria to join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

84 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Body mass index of ≥18 kg/m\^2 * eGFR ≥30 mL/min/1.73 m\^2 * Unequivocally positive ANA test result and/or a positive anti-dsDNA serum antibody test * Diagnosis of LN according to 2003 or 2018 ISN/RPS criteria and confirmed by renal biopsy performed within 12 months prior to Screening. * UPCR ≥1.0 (Class III/IV +/-V) or UPCR ≥2.0 (Class V) * Adequate hematologic, hepatic, and renal function Key Exclusion Criteria: * Current or medical history of: * Central nervous system manifestations of SLE * Overlapping autoimmune condition that may affect study assessments/outcomes * Antiphospholipid syndrome with history of thromboembolic event of within the 52 weeks prior to Screening * Thrombocytopenia or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies (i.e., plasmapheresis or acute blood or platelet transfusions * Solid organ transplant or planned transplant during study * Malignancy of any type, with exceptions for non-melanoma skin cancers and certain cancers \>5 years ago * Has received dialysis within the 52 weeks prior to Screening * Positive test at Screening for HIV, hepatitis B/C * Known intolerance to MMF or equivalent and corticosteroids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus nephritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus nephritis

Contacts and locations

Locations

  • Accurate Clinical Research - Lake Charles

    Lake Charles, Louisiana, 70605, United States

  • All India Institute of Medical Sciences

    Raipur, Chhattisgarh, 492099, India

  • Aprillus Assistance and Research by Arcis Health

    Buenos Aires, C1406AGA, Argentina

  • Assured Care Plus Hospital

    Nashik, Maharashtra, 422101, India

  • Austral University Hospital

    Pilar, B1629ODT, Argentina

  • Center for Advanced Health Clinical Studies

    Guatemala City, 01009, Guatemala

  • Clinical Hospital FMUSP

    São Paulo, 05403-000, Brazil

  • Clinical Research Center, S.A.

    Guatemala City, 01010, Guatemala

  • Clinics Hospital FMRP

    Ribeirão Preto, São Paulo, 14051-140, Brazil

  • Costa Clinica

    Barranquilla, Atlántico, 080020, Colombia

  • Dr. Doreski Medical Offices

    Buenos Aires, C1426ABP, Argentina

  • Elite Mission Hospital

    Thrissur, Kerala, 680007, India

  • Faculty of Medicine of SJRP

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Far Eastern University Hospital Nicanor Reyes Medical Foundation

    Quezon City, National Capital Region, 1118, Philippines

  • Framingham Medical Center

    Buenos Aires, B1902ADW, Argentina

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

  • Holy House of Mercy of Belo Horizonte

    Belo Horizonte, Minas Gerais, 30150-221, Brazil

  • Hospital Raja Permaisuri Bainun

    Ipoh, Perak, 30450, Malaysia

  • Hospital Selayang

    Batu Caves, Selangor, 68100, Malaysia

  • Hospital Sultan Idris Shah Serdang

    Kajang, Selangor, 43000, Malaysia

  • Iloilo Doctors' Hospital

    Iloilo City, Iloilo, 5000, Philippines

  • Jasleen Hospital

    Nagpur, Maharashtra, 440012, India

  • Kingsway Hospital

    Nagpur, Maharashtra, 440001, India

  • Krishna Institute of Medical Science

    Secunderabad, Telangana, 500003, India

  • Laiko General Hospital of Athens

    Athens, 11527, Greece

  • MGM Medical College and Hospital

    Aurangabad, Maharashtra, 431003, India

  • ManilaMed - Medical Center Manila

    Manila, National Capital Region, 1000, Philippines

  • Mary Mediatrix Medical Center

    Lipa City, Batangas, 4217, Philippines

  • Mayo Clinic of UCMB SRL

    San Miguel de Tucumán, Tucumán Province, T4000, Argentina

  • Medical Clinic Specialized in Internal Medicine and Rheumatology

    Guatemala City, 01010, Guatemala

  • Medical Clinic Specialized in Internal Medicine and Rheumatology

    Guatemala City, 01011, Guatemala

  • Medical Research Organization

    Buenos Aires, C1015, Argentina

  • Military Central Hospital

    Buenos Aires, C1426BOS, Argentina

  • Nephrology Associates, Inc

    East Providence, Rhode Island, 02914, United States

  • Nirmal Hospital

    Surat, Guajrat, 395002, India

  • Panchshil Hospital

    Ahmedabad, Gujarat, 380005, India

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, 518036, China

  • Phoenix Pharma

    Port Elizabeth, Eastern Cape, 6001, South Africa

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas, 76034, United States

  • Prince Court Medical Centre

    Kuala Lumpur, Kuala Lumpur, 50450, Malaysia

  • Prolato Clinical Research Center (PCRC)

    Houston, Texas, 77054, United States

  • SMS Medical College

    Jaipur, Rajasthan, 302001, India

  • Sir Ganga Ram Hospital

    New Delhi, NCT of Delhi, 110060, India

  • St. Luke's Medical Center

    Quezon City, National Capital Region, 1102, Philippines

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, 06591, South Korea

  • Unity Hospital

    Surat, Guajrat, 395010, India

  • University Malaya Medical Centre

    Kuala Lumpur, 59100, Malaysia

  • University of Santo Tomas Hospital

    Manila, 1015, Philippines

  • Yashoda Hospitals

    Hyderabad, Telangana, India, India

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.